首页> 外文期刊>BMC Psychiatry >An investigator-blinded, randomized study to compare the efficacy of combined CBT for alcohol use disorders and social anxiety disorder versus CBT focused on alcohol alone in adults with comorbid disorders: the Combined Alcohol Social Phobia (CASP) trial protocol
【24h】

An investigator-blinded, randomized study to compare the efficacy of combined CBT for alcohol use disorders and social anxiety disorder versus CBT focused on alcohol alone in adults with comorbid disorders: the Combined Alcohol Social Phobia (CASP) trial protocol

机译:一项针对研究人员的盲法随机研究,比较了合并CBT对酒精使用障碍和社交焦虑症与单纯合并CBT的成年人合并症患者的疗效:合并酒精社交恐惧症(CASP)试验方案

获取原文
           

摘要

Background Alcohol use disorders and social anxiety disorder are common and disabling conditions that frequently co-exist. Although there are efficacious treatments for each disorder, only two randomized controlled trials of interventions for these combined problems have been published. We developed a new integrated treatment for comorbid Social Anxiety Disorder and Alcohol Use Disorder based on established Motivational Interviewing (MI) and Cognitive Behaviour Therapy (CBT) interventions for the separate disorders. Compared to established MI/CBT for alcohol use disorders this new intervention is hypothesised to lead to greater reductions in symptoms of social anxiety and alcohol use disorder and to produce greater improvements in quality of life. Higher levels of alcohol dependence will result in relatively poorer outcomes for the new integrated treatment. Methods/design A randomised controlled trial comparing 9 sessions of individual integrated treatment for alcohol and social phobia with 9 sessions of treatment for alcohol use problems alone is proposed. Randomisation will be stratified for stable antidepressant use. Post treatment clinical assessments of alcohol consumption and diagnostic status at 3 and 6?month follow-up will be blind to allocation. Discussion The proposed trial addresses a serious gap in treatment evidence and could potentially define the appropriate treatment for a large proportion of adults affected by these problems. Trial registration Australian New Zealand Clinical Trials Registry: ACTRN12608000228381 .
机译:背景技术酒精使用障碍和社交焦虑障碍是常见的致残疾病,经常并存。尽管对每种疾病都有有效的治疗方法,但仅针对这些综合问题的干预措施进行了两项随机对照试验。我们针对既定疾病的动机访谈(MI)和认知行为疗法(CBT)干预措施,开发了针对合并症的社交焦虑症和饮酒障碍的新型综合治疗方法。与已建立的针对酒精使用障碍的MI / CBT相比,该新干预措施被认为可以更大程度地减少社交焦虑和酒精使用障碍的症状,并可以改善生活质量。更高程度的酒精依赖将导致新的综合治疗的相对较差的结果。方法/设计提出了一项随机对照试验,该试验比较了9个疗程的酒精和社交恐惧症个人综合治疗与9个疗程的酒精使用问题的单独治疗。为了稳定使用抗抑郁药,将进行随机分组。在治疗后3个月和6个月的随访中,对酒精消耗和诊断状态的临床评估将不予分配。讨论拟议的试验解决了治疗证据方面的严重空白,并可能为大多数受这些问题影响的成年人定义适当的治疗方法。试验注册澳大利亚新西兰临床试验注册:ACTRN12608000228381。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号